Towards third-generation whooping cough vaccines.
To date, the most significant use of recombinant-DNA technologies has been to hyperproduce natural molecules that are difficult to obtain in large quantities by conventional methods. However, genetic manipulation can also be an efficient way to modify the properties of natural molecules in order to make them more suitable for human use. In the development of third-generation whooping cough vaccines, recombinant-DNA methods were used to remove the enzymatic activity of pertussis toxin in order to obtain a new molecule which is devoid of toxicity, and can be used for safer vaccination against this disease.
Scalvo Research Center, Siena, Italy.
R
R
Rappuoli
M
M
Pizza
A
A
Podda
M T
MT
De Magistris
L
L
Nencioni
D000818:Animals; D000939:Epitopes; D006801:Humans; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology; D010566:Virulence Factors, Bordetella / Q000235:genetics / Q000276:immunology / Q000633:toxicity; D014917:Whooping Cough / Q000517:prevention & control*
D000939:Epitopes; D010567:Pertussis Vaccine; D014614:Vaccines, Synthetic; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin